Enterprise Value

2.304B

Cash

373.2M

Avg Qtr Burn

-48.73M

Short % of Float

12.96%

Insider Ownership

3.56%

Institutional Own.

-

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Marnetegragene autotemcel /RP-L201 (KRESLADI™) Details
Immunodeficiency, Leukocyte Adhesion Deficiency

Big Mover™

Susp. Mover™

PDUFA

Approval decision

RP-L102 Details
Rare diseases, Blood disorder, Fanconi Anemia

BLA

Submission

RP-L301 Details
Pyruvate Kinase Deficiency

Phase 2

Data readout

RP-A501 Details
Immunodeficiency, Danon Disease

Phase 2

Data readout

RP-A601 Details
Heart disease, Arrhythmogenic cardiomyopathy

Phase 1

Data readout

RP-L401 Details
Infantile Malignant Osteopetrosis

Failed

Discontinued